New Private Placement to Boost the Profitable Therapeutic Antibody Market

16/11/2016 - 2 minutes

MorphoSys has announced a private placement of shares to raise funds for its antibody therapy programs. With this push, the company is solidifying its position as a leader in the therapeutic antibody market, which is expected to reach €117B by 2021.

MorphoSys, one of the few European billion euro biotechs, develops therapeutic antibodies for immuno-oncology, inflammatory and autoimmune diseases. The German company has just announced a private placement of up to 10% of its share capital with the aim of raising funds to advance its antibody therapy pipeline.

The cash will push forward Morphosys’ proprietary antibody therapy programs to treat various types of blood cancer, all currently in Phase II. If everything goes well, the company expects to start Phase III with its lead candidate MOR208 in diffuse large B-cell lymphoma (DLBCL) next year. In addition, the funds will support MOR106, developed in partnership with Galapagos to treat atopic dermatitis, as well as other pre-clinical and clinical candidates.

Just in the third quarter of 2016,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member